紫杉醇脂质体联合卡培他滨治疗胃癌效果及对C-12多肿瘤标志物蛋白芯片水平的影响

Efficacy of Paclitaxel Liposome Combined with Capecitabine Regimen for Patients with Gastric Cancer and Its Effect on Protein Chip Level of C-12 Multiple Tumor Markers

目的探讨紫杉醇脂质体联合卡培他滨治疗胃癌的临床效果及对患者C-12多肿瘤标志物蛋白芯片水平的影响。方法选取武安市第一人民医院2015年7月至2018年7月收治的胃癌患者470例,随机分为观察组和对照组,各235例。对照组患者给予氟尿嘧啶联合顺铂方案治疗,观察组患者给予紫杉醇脂质体联合卡培他滨方案治疗。两组均以21 d为1个治疗周期,均连续治疗4个周期,门诊随访2年。结果治疗后,观察组客观缓解率为60.43%,疾病控制率为69.36%,分别高于对照组的50.64%和59.57%(P<0.05);治疗后,观察组患者的糖链抗原19-9、神经元特异性烯醇化酶、癌胚抗原、癌抗原242、癌抗原125、癌抗原15-3、甲胎蛋白、铁蛋白、游离型前列腺特异性抗原、前列腺特异性抗原、生长激素、绒毛膜促性腺激素β水平均明显低于对照组(P<0.05);生理功能、心理功能、社交功能、周围环境功能评分均明显高于对照组(P<0.05);观察组与对照组不良反应发生率相当(14.89%比17.45%,P>0.05);观察组局部复发率、远端转移率、死亡率均明显低于对照组(P<0.05)。结论紫杉醇脂质体联合卡培他滨治疗胃癌,能显著降低患者的C-12多肿瘤标志物蛋白水平,提高生活质量,降低局部复发率、远端转移率和死亡率。

Objective To study the clinical efficacy of paclitaxel liposome combined with capecitabine for patients with gastric cancer and its effect on protein chip level of C-12 tumor markers.Methods A total of 470 patients with gastric cancer admitted to Wu’an First People’s Hospital from July 2015 to July 2018 were selected and randomly divided into the observation group and control group,235 cases in each group.The control group was treated with fluorouracil plus cisplatin chemotherapy,and the observation group was treated with paclitaxel liposome combined with capecitabine.21 d was one treatment cycle,and both groups were continously treated for4 cycles.Results After treatment,the objective remission rate and disease control rate of the observation group were 60.43%and69.36%respectively,which were respectively higher than 50.64%and 59.57%of the control group(P<0.05);the protein chip level of C-12 multiple tumor markers in the observation group,including the levels of carbohydrate antigen 19-9,neuron specific enolase,carcinoembryonic antigen,carcinoembryonic antigen 242,carcinoembryonic antigen 125,carcinoembryonic antigen 15-3(CA15-3),alpha fetoprotein,ferritin,free prostate-specific antigen,prostate-specific antigen,human growth hormone and chorionic gonadotropinβ,were significantly lower than those of the control group(P<0.05);the scores of quality of life in the observation group,including physiological function,psychological function,social function and surrounding environment function,were higher than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(14.89%vs.17.45%,P>0.05);the local recurrence rate,distal metastasis and mortality of the observation group were significantly lower than those of the control group(P<0.05).Conclusion Paclitaxel liposome combined with capecitabine for gastric cancer can significantly reduce the protein chip level of C-12 tumor markers,improve the quality of life of patients,reduce the local recurrence rate,distal metastasis and mortality.